CN Patent

CN111606890A — 含丙烯酰基的核转运调节剂及其用途

Assigned to Wigen Biomedicine Technology Shanghai Co Ltd · Expires 2020-09-01 · 6y expired

What this patent protects

本发明涉及一类新型含丙烯酰基的化合物及其制备方法和用途。具体地，本发明涉及一类式(1)所示的含丙烯酰基的化合物及其制备方法，以及式(1)化合物及其药学上可接受的盐在制备治疗、调节和/或预防与CRM1相关的生理学病况相关的疾病药物中的用途。

USPTO Abstract

本发明涉及一类新型含丙烯酰基的化合物及其制备方法和用途。具体地，本发明涉及一类式(1)所示的含丙烯酰基的化合物及其制备方法，以及式(1)化合物及其药学上可接受的盐在制备治疗、调节和/或预防与CRM1相关的生理学病况相关的疾病药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN111606890A
Jurisdiction: CN
Classification: —
Expires: 2020-09-01
Drug substance claim: No
Drug product claim: No
Assignee: Wigen Biomedicine Technology Shanghai Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.